







an Open Access Journal by MDPI

# **Pharmacogenomics: Precision Medicine and Drug Response**

Guest Editor:

#### Dr. Emiliano Giardina

Genomic Medicine Laboratory
UILDM, Santa Lucia Foundation,
00142 Rome, Italy
 Forensic Genetics Laboratory,
Department of Biomedicine and
Prevention, Tor Vergata

University, 00133 Rome, Italy

Deadline for manuscript submissions:

closed (10 January 2022)

# **Message from the Guest Editor**

Over the years, many therapies have shown different efficacy profiles, supporting the development of precision medicine. Several pharmacogenomic approaches have been used to individualize treatments, optimizing dosage and preventing adverse effects. It is now possible to test the entire human genome to reveal positive associations between specific variations and the response to drugs in terms of efficacy and safety. Although numerous associations have been published, the translation to clinical practice in some areas has been minimal. A notable exception to this is the oncological field.

This Special Issue aims to curate available practical information in the pharmacogenomic domain to promote the translation of research data into precision medical protocols. Particular attention will be paid to new bioinformatic approaches to the interpretation of omic data and to research advances in populations that up to this point have little study data. At the same time, drug repurposing approaches will be encouraged to promote alternative applications of drugs with existing approval for use, and highlight innovations in the use of omic data in the treatment of human diseases













an Open Access Journal by MDPI

#### **Editor-in-Chief**

### Prof. Dr. Selvarangan Ponnazhagan

Department of Pathology, The University of Alabama at Birmingham, 1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

## Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

#### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank: JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))

#### **Contact Us**